My ePortfolio Register   

AACR 2014 /
Benefits found for lung cancer patients with high levels of PD-L1 with MK-3475 treatment

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 2002

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

At a press conference during AACR, Dr Gandhi discussed her study of the use of MK-3475 in lung cancer. According to the results of the phase 1 trial, those whose tumours had high levels of the protein PD-L1 had significantly better outcomes when treated with the investigational immunotherapy MK-3475.

Read the article for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence